Lovastatin
Product Images NDC 10544-246

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Lovastatin (NDC 10544-246). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Blenheim Pharmacal, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

20mg 30ct (Label Lovastatin Tabs 20mg Bpi(10544 246 30) Actavis(0228 2634 50) Rev0)

Label for Lovastatin Tablets, USP 20mg by Blenheim Pharmacal, Inc. The label shows a 30-tablet count bottle with NDC 10544-246-30. Storage instructions advise controlled room temperature (5°-25°C) and a light-resistant container. The label includes manufacturer and distributor information, lot number BP00000000, and placeholder expiration date 00/00/0000.*

FDA Label Image

Imprint1 (Current R1)

Lovastatin tablet bottle label from Blenheim Pharmacal, Inc., showing the product name Lovastatin prominently and the product NDC 10544-246. The label has text details including directions and warnings, and the bottle cap is child-resistant with a push-and-turn feature.*

FDA Label Image

Imprint2 (Current R2)

Lovastatin 20 mg tablets packaging from Blenheim Pharmacal, Inc. The label displays the product name Lovastatin, strength 20 mg, tablet dosage form, and includes the labeler information Blenheim Pharmacal, Inc. The packaging prominently shows the product NDC 10544-246.*

FDA Label Image

Imprint3 (Current R3)

Lovastatin tablet bottle label from Blenheim Pharmacal, Inc. The label includes the proprietary name Lovastatin, specifying tablets as the dosage form. The product NDC 10544-246 is also visible. The label features standard drug labeling details on a white bottle with a white cap.*

FDA Label Image

Structure (Current Tmp200922115041699)

Chemical structure diagram of Lovastatin showing its molecular components including rings, hydroxyl, carbonyl, and methyl groups, consistent with the active ingredient Lovastatin.*

FDA Label Image

Figure 1 (Current Tmp200922115041918)

A line graph titled 'Acute Major Coronary Events (Primary Endpoint)' comparing the proportion of participants without events over approximately 6 years of follow-up between Lovastatin and placebo groups. The Lovastatin group shows higher event-free proportions, with a noted 37% risk reduction and statistical significance (p<0.001). The x-axis represents years of follow-up and the y-axis shows the proportion of participants without events.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.